January 26, 2022
Video
The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas discussed how the momentum gained within the Alzheimer community can springboard success going forward. [WATCH TIME: 4 minutes]
January 05, 2022
Video
The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success. [WATCH TIME: 4 minutes]
December 03, 2021
Video
The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed the positive trends within the Alzheimer drug development space. [WATCH TIME: 2 minutes]
August 24, 2020
Video
The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada-Las Vegas discussed the role repurposed agents play in Alzheimer disease development.
August 08, 2020
Video
The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada–Las Vegas discussed the leading challenges for those with Alzheimer disease.
July 29, 2020
Video
The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada­–Las Vegas gives his thoughts on the latest aducanumab update and its potential as a treatment for Alzheimer disease.
July 24, 2020
Video
The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada-Las Vegas, details trends in Alzheimer disease research over the past few years.
Interdisciplinary Care and Hot Topics in Movement Disorders: Jill Farmer, DO, MPH
Phase 2b Study of Parkinson Disease LRRK Inhibitor BIIB122 Initiated
AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight
Evusheld Increased Attenuated SARS-CoV-2 Antibodies From MS B-Cell Depleting Medications